What lies ahead for the cell and gene therapy market?

Major investors have committed over $3.5b across cumulative deals.

The cell and gene therapy (CGT) market is expected to grow 34.2% annually until 2031 on the back of increased therapeutic approvals, according to a GlobalData report.

Approximately half (50%) of CGT venture capital is focused on the Series B-stage, as companies shift from platform validation to clinical execution.

CGT capital deployment remains highly concentrated amongst a small group of major investors, who have committed over $3.5b across cumulative deals.

Meanwhile, large key players are actively adopting CGT technologies into their pipelines through acquisition deals.

“Such acquisitions are becoming increasingly modality-driven and focused on platforms, scalable manufacturing systems, and specialised capabilities that can support portfolio-wide CGT expansion efforts,” said Irena Maragkou, Senior Healthcare Researcher at GlobalData.

Merger and acquisition activity focused on non-oncology CGT assets, whilst oncology-focused deals remain heavily centred on early research and development and gene-modified cell therapies.

However, firms must prepare for regulatory complexity and manufacturing scalability, Maragkou noted.

“Biotech companies need to be strategic in investing in differentiated technologies and build execution capabilities to deliver clinical and commercial impact,” the researcher added.